Versant Vantage II, L.P.
CIK 0001832235 Name as filed on the most recent filing
Filed as Versant Vantage II, L.P. (13)
43 transaction lines · from 13 filings · filed 2021-06-23 to 2025-10-02 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Lenz Therapeutics, Inc. 9 filings
- ISSUER Tempest Therapeutics, Inc. 1 filings
- ISSUER Turnstone Biologics Corp. 1 filings
- ISSUER Century Therapeutics, Inc. 2 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2025-09-30 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 83,066 disposed | 46.41 | 3,854,827.25 | Form 4, filing 0001193125-25-228493 | |
| 2025-09-30 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 57,502 disposed | 46.41 | 2,668,483.81 | Form 4, filing 0001193125-25-228493 | |
| 2025-09-30 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 49,701 disposed | 45.35 | 2,254,173.94 | Form 4, filing 0001193125-25-228493 | |
| 2025-09-30 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 34,405 disposed | 45.35 | 1,560,428.45 | Form 4, filing 0001193125-25-228493 | |
| 2025-09-30 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 177 disposed | 47.01 | 8,321.35 | Form 4, filing 0001193125-25-228493 | |
| 2025-09-30 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 123 disposed | 47.01 | 5,782.64 | Form 4, filing 0001193125-25-228493 | |
| 2025-09-18 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 49,479 disposed | 41.59 | 2,057,871.19 | Form 4, filing 0001193125-25-211363 | |
| 2025-09-18 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 40,907 disposed | 43.00 | 1,759,156.45 | Form 4, filing 0001193125-25-211363 | |
| 2025-09-18 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 24,370 disposed | 41.59 | 1,013,567.80 | Form 4, filing 0001193125-25-211363 | |
| 2025-09-18 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 20,148 disposed | 43.00 | 866,440.56 | Form 4, filing 0001193125-25-211363 | |
| 2025-09-18 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 268 disposed | 43.30 | 11,604.40 | Form 4, filing 0001193125-25-211363 | |
| 2025-09-18 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 132 disposed | 43.30 | 5,715.60 | Form 4, filing 0001193125-25-211363 | |
| 2025-08-26 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 43,978 disposed | 38.97 | 1,714,016.16 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-26 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 21,661 disposed | 38.97 | 844,224.48 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-26 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 3,465 disposed | 39.50 | 136,875.12 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-26 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 1,707 disposed | 39.50 | 67,430.26 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-25 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 50,270 disposed | 39.53 | 1,986,946.88 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-25 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 24,760 disposed | 39.53 | 978,651.38 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-25 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 2,149 disposed | 39.92 | 85,790.66 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-25 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 1,058 disposed | 39.92 | 42,236.63 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-22 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 20,493 disposed | 40.03 | 820,328.64 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-22 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 10,076 disposed | 40.03 | 403,339.26 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-22 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 5,668 disposed | 40.59 | 230,063.55 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-22 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 2,809 disposed | 40.59 | 114,017.03 | Form 4, filing 0000950170-25-111529 | |
| 2025-08-18 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 30,628 disposed | 38.56 | 1,181,049.37 | Form 4, filing 0000950170-25-110163 | |
| 2025-08-18 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 15,085 disposed | 38.56 | 581,694.19 | Form 4, filing 0000950170-25-110163 | |
| 2025-08-15 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 145,051 disposed | 39.50 | 5,729,514.50 | Form 4, filing 0000950170-25-110163 | |
| 2025-08-15 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 69,949 disposed | 39.50 | 2,762,985.50 | Form 4, filing 0000950170-25-110163 | |
| 2025-07-10 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 191,376 disposed | 34.00 | 6,506,784.00 | Form 4, filing 0000950170-25-095616 | |
| 2025-06-27 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 200,000 disposed | 30.46 | 6,093,000.00 | Form 4, filing 0000950170-25-092373 | |
| 2025-06-20 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 133,924 disposed | 30.25 | 4,051,201.00 | Form 4, filing 0000950170-25-088604 | |
| 2025-06-20 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 100,877 disposed | 30.35 | 3,061,616.95 | Form 4, filing 0000950170-25-088604 | |
| 2025-06-18 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 100,000 disposed | 29.95 | 2,995,000.00 | Form 4, filing 0000950170-25-088604 | |
| 2025-06-10 |
Lenz Therapeutics, Inc. LENZ |
S, Open-market sale | 350,000 disposed | 29.00 | 10,150,000.00 | Form 4, filing 0000950170-25-085490 | |
| 2024-08-12 |
Tempest Therapeutics, Inc. TPST |
S, Open-market sale | 387,999 disposed | 1.10 | 426,992.90 | Form 4, filing 0000950170-24-095675 | |
| 2024-08-08 |
Tempest Therapeutics, Inc. TPST |
S, Open-market sale | 400,000 disposed | 1.35 | 540,040.00 | Form 4, filing 0000950170-24-095675 | |
| 2023-07-25 |
Turnstone Biologics Corp. TSBX |
P, Open-market purchase | 197,458 acquired | 12.00 | 2,369,496.00 | Form 4, filing 0001209191-23-043527 | |
| 2023-07-25 |
Turnstone Biologics Corp. TSBX |
P, Open-market purchase | 15,028 acquired | 12.00 | 180,336.00 | Form 4, filing 0001209191-23-043527 | |
| 2023-07-25 |
Turnstone Biologics Corp. TSBX |
P, Open-market purchase | 6,575 acquired | 12.00 | 78,900.00 | Form 4, filing 0001209191-23-043527 | |
| 2023-07-25 |
Turnstone Biologics Corp. TSBX |
P, Open-market purchase | 5,939 acquired | 12.00 | 71,268.00 | Form 4, filing 0001209191-23-043527 | |
| 2022-08-09 |
Century Therapeutics, Inc. IPSC |
S, Open-market sale | 550,000 disposed | 13.03 | 7,166,610.00 | Form 4, filing 0000899243-22-028388 | |
| 2021-06-29 |
Graphite Bio, Inc. GRPH |
P, Open-market purchase | 180,000 acquired | 17.00 | 3,060,000.00 | Form 4, filing 0000899243-21-027018 | |
| 2021-06-22 |
Century Therapeutics, Inc. IPSC |
P, Open-market purchase | 100,000 acquired | 20.00 | 2,000,000.00 | Form 4, filing 0001104659-21-084643 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Versant Vantage II, L.P., insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001832235
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6